News

Blood levels of nesfatin-1, irisin, adropin, and preptin — all regulatory hormones known to control energy balance — are significantly reduced in multiple sclerosis (MS) patients relative to healthy people, a small study showed. While the implications of these findings remain unclear, the…

A new tool that analyzes gait, or walking patterns, of people on a treadmill — using video recordings from a simple digital camera — is able to accurately identify those with multiple sclerosis (MS), a study showed. Scientists said the gait-analysis tool may be a low-cost and easy-to-use way…

People with multiple sclerosis (MS) are significantly more likely to have antibodies against the Epstein-Barr virus (EBV) — the strongest risk factor for the disease — than healthy individuals, as well as higher levels of these antibodies, according to a Spanish study. All MS patients were positive for anti-EBV…

NexImmune is working with the National Institute of Neurological Disorders and Stroke (NINDS) to develop cell therapies for people with immunological disorders associated with certain viral infections, namely the Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1). A history of infection with EBV — mostly…

Data passively collected by smartphone apps and fitness trackers can be used to accurately predict the risk of depression, severe fatigue, poor sleep quality, and symptom worsening in people with multiple sclerosis (MS) when in-person health visits are suddenly limited. These are the findings of a small study that…

The risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) declined significantly after the introduction of disease-modifying therapies (DMT), according to a large nationwide Swedish study. Data showed that SPMS conversion risk rose by 3% each year before the first generation of…

Among children and adolescents with multiple sclerosis (MS), treatment with Tecfidera (dimethyl fumarate) resulted in less disease activity on MRI scans and fewer relapses, compared with Avonex (interferon beta-1a), according to new data from the CONNECT Phase 3 trial. Researchers noted the lack of disease-modifying therapies…

Neurologists in Colombia agree that sexual dysfunction is burdensome and affects quality of life in major ways for people with multiple sclerosis (MS), but some still don’t ask their patients about it, a survey study reported. Findings also revealed that many neurologists there do not use formal tools…

Multiple sclerosis (MS) patients who started taking Tysabri (natalizumab) long after their diagnosis were found to have worsened disease progression. But those who began using it earlier showed less aggravated clinical and radiological outcomes of the disease than participants who started treatment later, a study showed. The study,…

A novel tracer designed to detect myelin loss in PET scans — imaging tests that use a radioactive substance, called a tracer, to look for disease in the body — showed a good safety profile in a small first-in-human study. Scientists say this new tracer could potentially help in evaluating…

mSteps, a new phone app, could be used to precisely measure the outdoor walking distance of people affected by multiple sclerosis (MS), a recent study shows. The study, “The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis,” was published in…

XRHealth‘s virtual reality (VR) software, which provides an immersive three-dimensional environment where patients do repetitive tasks such as popping a balloon with a sword, is safe and feasible for upper limb training among people with multiple sclerosis (MS), according to a recent pilot study. Participants generally felt engaged…

Electrical stimulation of the brain through electrodes placed on the scalp may ease some measures of spasticity for people with relapsing-remitting multiple sclerosis (RRMS), according to results from a small clinical trial. Using this novel route of brain stimulation was shown to impact muscle contractions in patients with spasticity…

Evaluating a person’s sense of smell may help monitor disease progression in people with multiple sclerosis (MS), according to a recent study. Almost a third of MS patients studied showed signs of smell loss in clinical evaluations and the degree of impairment correlated with clinical measures of disease, such…

The presence of iron rim lesions, which are regions of chronic inflammation seen on MRI scans, may be linked to a more severe disease course in people with multiple sclerosis (MS), according to a recent study. The findings suggest the presence and number of iron rim lesions could serve…

Autologous hematopoietic stem cell transplant (aHSCT) reduces markers of nerve fiber and myelin damage in people with relapsing-remitting MS (RRMS), according to a small study done in Sweden. “We investigated if therapeutic intervention with aHSCT could halt the injurious process leading to tissue damage in MS,” researchers wrote.

Bionic clothing innovator Cionic has received $12.5 million to further develop a platform that produces wearable, artificial intelligence-powered garments for people with mobility issues. The platform has helped create the Neural Sleeve, a leg-worn garment that enables people with conditions such as multiple sclerosis (MS) to become more…

Guar gum, a type of dietary fiber that can be taken as a supplement, lessened inflammation and disease severity in a mouse model of multiple sclerosis (MS), a new study reports. While fiber-rich diets have long been recommended to improve overall health, these findings help pinpoint which fibers have…

Treatment with interferon beta (IFN-beta) — a disease-modifying therapy that lowers inflammation in multiple sclerosis (MS) — was found to restore the ability of blood vessels in the brain to dilate following a stimulus. A new study suggests that this ability, called cerebrovascular reactivity or CVR, is reduced…

A quick MRI-based method called SyMRI may be useful in future clinical trials to test experimental myelin-repairing therapies in diseases like multiple sclerosis (MS), a new study shows. The study, “Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging,” was published in Brain…

The Overall Disability Response Score, a combination of three different assessments of disability, could be used to more accurately evaluate the effectiveness of treatments in multiple sclerosis (MS) clinical trials, a new study illustrates. The score is composed of three measures commonly used to assess disability in MS, which…

To help ensure that more multiple sclerosis (MS) patients get specialized care, the Michigan Institute for Neurological Disorders (MIND) has opened a physician fellowship program for neurologists. The one-year program is led by Martin Belkin, MD, a neurologist who specializes in MS research and care at MIND, a private…

Kesimpta (ofatumumab) is more cost-effective for treating relapsing-remitting multiple sclerosis (RRMS) than most other disease-modifying therapies (DMTs) approved in Canada, according to a new analysis. The analysis indicated that Kesimpta is generally more effective and associated with fewer costs than the majority of MS treatments, with the…

A new machine learning tool could help make clinical trials for progressive forms of multiple sclerosis (MS) more efficient and effective, a study suggests. Its scientists propose that the tool, when used in initial patient studies, works to more rapidly move a potential progressive MS treatment into pivotal Phase…

Even in early stages of disease, people with multiple sclerosis (MS) commonly experience more difficulties performing cognitive and motor tasks simultaneously than do people without MS, a new study indicates. The study, “Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy…

The U.S. Patent and Trademark Office will grant Trethera Corp. a new patent covering the composition and chemical structure of TRE-515, an experimental oral therapy being developed for multiple sclerosis (MS) and cancer. The patent number 11,446,307, titled “Crystalline forms of a deoxycytidine kinase inhibitor and…

People with multiple sclerosis (MS) may be more likely to use unhealthy or ineffective coping mechanisms than healthy individuals — and these “maladaptive strategies” are linked to worse mood and a poorer quality of life among patients, according to a new review study. Rather than also relying on active…

The rates of pregnancy complications are not higher in women with multiple sclerosis (MS) who were using disease-modifying therapies (DMTs) in the earliest stages of pregnancy, a study reported. The study, “Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate or natalizumab in…

The likelihood of survival is about 7.5 times higher for people with multiple sclerosis (MS) who take their disease-modifying treatments as directed compared with those who do not, an analysis of data from U.S. veterans shows. The study, “Impact of Adherence with Disease-Modifying Therapies on All-Cause…

Novartis said it will petition the U.S. Supreme Court to uphold a patent that protects the dosing regimen of Gilenya (fingolimod) that’s approved for relapsing forms of multiple sclerosis (MS). The original patent was not set to expire until the end of 2027, which meant generic versions…